Pharming Q1 2024 GAAP EPS $(0.02) Misses $0.01 Estimate, Sales $55.586M Miss $68.425M Estimate
Pharming Q1 2024 GAAP EPS $(0.02) Misses $0.01 Estimate, Sales $55.586M Miss $68.425M Estimate
制药业2024年第一季度GAAP每股收益（0.02）未达到0.01美元的预期，5,5586万美元的销售额低于6,8425万美元的预期
Pharming (NASDAQ:PHAR) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $0.01 by 290 percent. This is unchanged from the same period last year. The company reported quarterly sales of $55.586 million which missed the analyst consensus estimate of $68.425 million by 18.76 percent. This is a 30.66 percent increase over sales of $42.541 million the same period last year.
制药（纳斯达克股票代码：PHAR）公布的季度亏损为每股0.02美元，比分析师普遍预期的0.01美元低290％。这与去年同期相比没有变化。该公司公布的季度销售额为5,5586万美元，比分析师普遍预期的6,8425万美元低18.76％。这比去年同期的4,2541万美元销售额增长了30.66％。